Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Int J Environ Res Public Health. 2009 Sep;6(9):2510-25. doi: 10.3390/ijerph6092510. Epub 2009 Sep 23.

A multicenter, randomized, open-labeled, parallel group trial of sildenafil in alcohol-associated erectile dysfunction: the impact on psychosocial outcomes.

Author information

  • 1Mental Health Services, Ministry of Health, Jerusalem 93591, Israel. alexander.ponizovsky@moh.health.gov.il

Abstract

To examine the effect of sildenafil on erectile dysfunction (ED) and psychosocial outcomes in alcohol-dependent (AD) men, 108 men with these diagnoses were randomly assigned to either take sildenafil (50 mg) as add-on to standard treatment for AD, or the same treatment without sildenafil, for 12 weeks. Only 50 patients in sildenafil group and 51 in control group twice completed the International Index of Erectile Function (IIEF) and a battery of self-report questionnaires. IIEF scores and psychosocial functioning, self-esteem and support from friends improved only for sildenafil-treated patients (P < 0.001). The high effect sizes suggest that the observed benefits are unlikely to be a placebo effect, although their unspecific nature could not be ruled out. In men with ED associated with AD, sildenafil improves both ED and psychosocial outcomes. Further placebo-controlled clinical trial is warranted.

KEYWORDS:

alcohol dependence; depression; erectile dysfunction; functioning; self-esteem; sildenafil; social support

PMID:
19826560
[PubMed - indexed for MEDLINE]
PMCID:
PMC2760426
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
    Loading ...
    Write to the Help Desk